Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 13/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419550 | 0.96 | MC4R (0.52) | MC4RGHSRKISS1R | |
| SCHEMBL29419493 | 0.96 | MC4R (0.52) | MC4RGHSRKISS1R | |
| SCHEMBL31555133 | 0.96 | MC4R (0.52) | MC4RGHSRKISS1R | |
| SCHEMBL30878116 | 0.94 | GHSR (0.52) | MC4RGHSRKISS1R | |
| SCHEMBL30878110 | 0.93 | GHSR (0.53) | MC4RGHSRKISS1R | |
| SCHEMBL29476499 | 0.93 | MC4R (0.50) | MC4RGHSRKISS1R | |
| SCHEMBL30878109 | 0.93 | GHSR (0.54) | MC4RGHSRKISS1R | |
| SCHEMBL30615758 | 0.93 | KISS1R (0.63) | KISS1R | |
| SCHEMBL29862113 | 0.93 | KISS1R (0.63) | KISS1R | |
| SCHEMBL30725663 | 0.93 | MC4R (0.49) | MC4RGHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2025-04-24 | — | — | US | disclosed |
| US-12173087-B2 | Melanocortin 1 receptor ligands and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230167154-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-7087759-B2 | for controlling weight; pyrrolidine or piperidine compounds | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060106059-A1 | Melanocortin receptor ligands | MAZUR WIESLAW A | 2006-05-18 | — | — | US | disclosed |
| US-6911447-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040224985-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2004-11-11 | — | — | US | disclosed |
| US-20030109556-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109556-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | MC4R 2/4885GHSR 60/4885KISS1R 109/4885 |
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | MC1R, MC3R, MCHR1 | MC4R 8/4885GHSR 215/4885KISS1R 100/4885 |
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | MC1R, MC3R, MC5R | MC4R 5/4885GHSR 65/4885KISS1R 41/4885 |
| US-20060106059-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | MC4R 2/4885GHSR 62/4885KISS1R 261/4885 |
| US-12173087-B2 | Melanocortin 1 receptor ligands and methods of use | MC1R, MC3R, MC5R | MC4R 5/4885GHSR 66/4885KISS1R 41/4885 |
| US-20230167154-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | MC4R 5/4885GHSR 65/4885KISS1R 41/4885 |
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | MC1R, MC3R, MCHR1 | MC4R 8/4885GHSR 215/4885KISS1R 100/4885 |
| US-20040224985-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | MC4R 2/4885GHSR 60/4885KISS1R 109/4885 |
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | MC4R 5/4885GHSR 65/4885KISS1R 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.